GT Biopharma Inc.

NASDAQ: GTBP · Real-Time Price · USD
2.89
0.22 (8.24%)
At close: May 23, 2025, 3:59 PM
2.76
-4.50%
After-hours: May 23, 2025, 05:56 PM EDT

Company Description

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform.

It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.

The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors.

GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology.

The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017.

GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

GT Biopharma Inc.
GT Biopharma Inc. logo
Country United States
IPO Date Mar 27, 2018
Industry Biotechnology
Sector Healthcare
Employees 1
CEO Alan Louis Urban CPA

Contact Details

Address:
8000 Marina Boulevard
San Francisco, California
United States
Website https://www.gtbiopharma.com

Stock Details

Ticker Symbol GTBP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000109657
CUSIP Number 36254L209
ISIN Number US36254L3087
Employer ID 94-1620407
SIC Code 2834

Key Executives

Name Position
Alan Louis Urban CPA Chief Financial Officer & Secretary

Latest SEC Filings

Date Type Title
May 15, 2025 10-Q Quarterly Report
May 14, 2025 SCHEDULE 13G Filing
May 13, 2025 8-K Current Report
May 13, 2025 8-K Current Report
May 05, 2025 8-K Current Report
Apr 14, 2025 10-K/A [Amend] Annual Report
Apr 04, 2025 8-K Current Report
Mar 14, 2025 424B3 Filing
Mar 07, 2025 D Filing
Mar 06, 2025 S-3 Filing